

CITATION REPORT

List of articles citing

In vivo detection of *Trypanosoma cruzi* antigens in hearts of patients with chronic Chagaspheart disease

DOI: 10.1016/s0002-8703(96)90358-0
American Heart Journal, 1996, 131, 301-7.

Source: <https://exaly.com/paper-pdf/26749789/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
121	American Trypanosomiasis (ChagasSDisease). 1994 , 1082-1094		3
120	Persistent production of inflammatory and anti-inflammatory cytokines and associated MHC and adhesion molecule expression at the site of infection and disease in experimental Trypanosoma cruzi infections. 1996 , 84, 203-13		50
119	Antibodies to ribosomal P proteins of Trypanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus. 1997 , 94, 10301-6		88
118	"Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue. 1997 , 94, 3932-7		117
117	Molecular mimicry between cardiac myosin and Trypanosoma cruzi antigen B13: identification of a B13-driven human T cell clone that recognizes cardiac myosin. 1997 , 30, 1305-8		31
116	Reply. 1997 , 13, 362-363		1
115	ChagasSDisease and the autoimmunity hypothesis. 1999 , 12, 210-23		133
114	Parasite persistence correlates with disease severity and localization in chronic ChagasSDisease. 1999 , 180, 480-6		216
113	Local and systemic cytokine expression during experimental chronic Trypanosoma cruzi infection in a Cebus monkey model. 1999 , 21, 451-60		16
112	Chagas disease etiology: autoimmunity or parasite persistence?. 1999 , 15, 94-9		169
111	Relation between interstitial myocardial collagen and the degree of clinical impairment in ChagasS disease. 1999 , 84, 354-6, A9		36
110	Trypanosoma cruzi, agent de la maladie de Chagas ou trypanosomose amricaine. 1999 , 10, 51-65		
109	Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi antigens. 2000 , 94, 571-9		61
108	Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. 2000 , 102, 3003-8		195
107	Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in ChagasScardiomyopathy. 2000 , 86, 975-81		87
106	ChagasSheart disease. 2000 , 23, 883-9		221
105	Upregulation of adhesion molecules and class I HLA in the myocardium of chronic chagasic cardiomyopathy and heart allograft rejection, but not in dilated cardiomyopathy. 2000 , 9, 111-7		15

104	The paradox of survival results after heart transplantation for cardiomyopathy caused by <i>Trypanosoma cruzi</i> . First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. 2001 , 71, 1833-8		128
103	Ventricular tachycardia syndromes. 2001 , 85, 267-304		12
102	Nuclear Medicine in Tropical and Infectious Diseases. 2002 ,		0
101	Cruzipain induces both mucosal and systemic protection against <i>Trypanosoma cruzi</i> in mice. <i>Infection and Immunity</i> , 2002 , 70, 5065-74	3.7	68
100	Changing Epidemiology and Approaches to Therapy for Chagas Disease. 2003 , 5, 59-65		18
99	Views on the autoimmunity hypothesis for Chagas disease pathogenesis. 2003 , 37, 1-11		32
98	Use of a purified <i>Trypanosoma cruzi</i> antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. 2003 , 22, 77-86		47
97	Profiling gene transcription reveals a deficiency of mitochondrial oxidative phosphorylation in <i>Trypanosoma cruzi</i> -infected murine hearts: implications in chagasic myocarditis development. 2003 , 1638, 106-20		83
96	Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction. 2003 , 89, 1186-90		71
95	Current concepts of the irritable bowel syndrome. 2003 , 1-8		29
94	The significance of autoimmunity in the pathogenesis of Chagas heart disease. 2003 , 8, e315-22		45
93	The role of nitric oxide in the pathogenesis of Chagas disease. 2003 , 8, s314-25		69
92	Immunological tolerance and its breakdown in Chagas heart disease: role of parasitokines. 2003 , 8, e218-27		6
91	Cardiovascular magnetic resonance imaging: current applications and future directions. 2004 , 386, 122-48		5
90	Modulatory effects on myocardial physiology induced by an anti- <i>Trypanosoma cruzi</i> monoclonal antibody involve recognition of major antigenic epitopes from beta1-adrenergic and M2-muscarinic cholinergic receptors without requiring receptor cross-linking. 2004 , 153, 99-107		12
89	Cardiovascular magnetic resonance imaging: current and emerging applications. 2004 , 44, 1164-71		137
88	Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?. 2005 , 6, 122-32		47
87	The <i>Trypanosoma cruzi</i> -host-cell interplay: location, invasion, retention. 2005 , 3, 819-23		185

86	Nonischemic Myocardial Disease. 2005 , 217-270	2
85	Chagas Myocarditis and Syncope. 2005 , 7, 685-688	13
84	Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon. 2005 , 34, 221-33, vi	42
83	Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. 2005 , 184, 1420-6	155
82	Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: current applications and future perspectives. 2006 , 11, 313-23	31
81	MRI to assess arrhythmia and cardiomyopathies. 2006 , 24, 1197-206	12
80	Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. 2007 , 179, 6889-900	77
79	Clinical aspects of the ChagasHeart disease. 2007 , 115, 279-83	89
78	Etiological treatment of chronic Chagas disease: neglected Se evidenceSby evidence-based medicine. 2007 , 5, 717-26	60
77	Pathogenesis of chronic Chagas heart disease. 2007 , 115, 1109-23	526
76	Diagn�stico, manejo y tratamiento de la cardiopat� chag�tica cr�nica en �reas donde la infecci� por Trypanosoma cruzi no es end�mica. 2007 , 60, 285-293	47
75	Diagnosis, Management, and Treatment of Chronic ChagasHeart Disease in Areas Where Trypanosoma cruzi Infection Is Not Endemic. 2007 , 60, 285-293	4
74	Bradykinin B2 Receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses. 2007 , 3, e185	68
73	Ablation of Ventricular Tachycardia Associated with Nonischemic Structural Heart Disease. 342-363	
72	Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. 2007 , 40, 1-10	155
71	. 2007 ,	2
70	Immunologically relevant strain polymorphism in the Amastigote Surface Protein 2 of Trypanosoma cruzi. 2007 , 9, 1011-9	24
69	Bioluminescent imaging of Trypanosoma cruzi infection. 2008 , 38, 1391-400	47

68	[Diagnosis, management and treatment of chronic ChagasHeart disease in areas where Trypanosoma cruzi infection is not endemic]. 2008 , 26, 99-106		15
67	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in ChagasScardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). <i>American Heart Journal</i> , 2008 , 156, 37-43	4.9	153
66	Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. 2008 , 102, 481-7		59
65	Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. <i>Infection and Immunity</i> , 2008 , 76, 324-33	3.7	76
64	Chagas heart disease pathogenesis: one mechanism or many?. 2008 , 8, 510-8		117
63	The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. 2009 , 104 Suppl 1, 319-24		132
62	Do Archaea and bacteria co-infection have a role in the pathogenesis of chronic chagasic cardiopathy?. 2009 , 104 Suppl 1, 199-207		5
61	Applications of cardiac magnetic resonance in electrophysiology. 2009 , 2, 63-71		15
60	The role of parasite persistence in pathogenesis of Chagas heart disease. 2009 , 31, 673-85		131
59	Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. 2009 , 104 Suppl 1, 122-35		75
58	Chagas cardiomyopathy--where do we stand after a hundred years?. 2010 , 52, 300-16		107
57	Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. 2010 , 3, 82-8		71
56	Exercise training in ChagasScardiomyopathy: trials are welcome for this neglected heart disease. 2010 , 12, 782-4		14
55	Pathological Consequences of Host Response to Parasite. 2010 , 669-690		
54	Chagas disease: progress and new perspectives. 2010 , 17, 423-52		45
53	Current status of Chagas disease chemotherapy. 2011 , 9, 609-20		88
52	Prevalence of Trypanosoma cruzi antibodies and inflammatory markers in uncompensated heart failure. 2011 , 44, 691-6		6
51	Heart Muscle Diseases. <i>Medical Radiology</i> , 2011 , 275-353		0.2

50	Device therapy in Chagas disease heart failure. 2012 , 10, 1307-17	7
49	Host cell invasion by <i>Trypanosoma cruzi</i> : a unique strategy that promotes persistence. 2012 , 36, 734-47	78
48	Antiparasitical chemotherapy in Chagas disease cardiomyopathy: current evidence. 2012 , 17, 1057-65	19
47	The reality of heart failure in Latin America. 2013 , 62, 949-58	64
46	Mode of death on Chagas heart disease: comparison with other etiologies. a subanalysis of the REMADHE prospective trial. 2013 , 7, e2176	36
45	<i>Trypanosoma cruzi</i> Entrance through Systemic or Mucosal Infection Sites Differentially Modulates Regional Immune Response Following Acute Infection in Mice. 2013 , 4, 216	14
44	Heart failure in South America. 2013 , 9, 147-56	62
43	Chagas disease in the immunosuppressed patient. 2014 , 20, 300-9	54
42	<i>Trypanosoma cruzi</i> P21: a potential novel target for chagasic cardiomyopathy therapy. 2015 , 5, 16877	14
41	Arrhythmias in chagasic cardiomyopathy. 2015 , 7, 251-68	29
40	Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead. 2015 , 185, 1537-47	73
39	Randomized Trial of Benznidazole for Chronic Chagas Cardiomyopathy. 2015 , 373, 1295-306	605
38	Putting Infection Dynamics at the Heart of Chagas Disease. 2016 , 32, 899-911	53
37	Inmunidad celular en la patogénesis de la cardiopatía chagásica crónica. 2016 , 23, 568-575	0
36	Biological factors that impinge on Chagas disease drug development. 2017 , 144, 1871-1880	31
35	Inflammatory Cardiomyopathic Syndromes. 2017 , 121, 803-818	134
34	Chronic Chagas Heart Disease Management: From Etiology to Cardiomyopathy Treatment. 2017 , 70, 1510-1524	84
33	Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. 2017 , 112, 224-235	105

32	Chagas Cardiomyopathy. 2017 , 553-574		1
31	Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. 2018 , 5, 249-256		15
30	Archaea Symbiont of Infection May Explain Heart Failure in Chagas Disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018 , 8, 412	5.9	2
29	Diagnosis and Management of Chagas Cardiomyopathy in the United States. 2018 , 20, 131		6
28	Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. 2018 , 138, e169-e209		177
27	Experimental evidences that P21 protein controls Trypanosoma cruzi replication and modulates the pathogenesis of infection. 2019 , 135, 103618		2
26	Progression of Baseline Electrocardiogram Abnormalities in Chagas Patients Undergoing Antitrypanosomal Treatment. 2019 , 6, ofz012		7
25	Neurotrophic Factor Facilitates Cardiac Repair in a Mouse Model of Chronic Chagas Disease. 2019 , 368, 11-20		2
24	Cardiac magnetic resonance imaging in Chagas Disease: a parallel with electrophysiologic studies. 2020 , 36, 2209-2219		3
23	Application of single-cell transcriptomics to kinetoplastid research. 2021 , 148, 1223-1236		6
22	Advanced Therapies for Ventricular Arrhythmias in Patients With Chagasic Cardiomyopathy: JACC State-of-the-Art Review. 2021 , 77, 1225-1242		2
21	Does Autoimmunity Play a Role in the Immunopathogenesis of Vasculitis Associated With Chronic Chagas Disease?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 671962	5.9	
20	HIF-1 and CD73 expression in cardiac leukocytes correlates with the severity of myocarditis in end-stage Chagas disease patients. <i>Journal of Leukocyte Biology</i> , 2021 , 109, 233-244	6.5	2
19	Chagas Disease: An Unknown and Neglected Disease. 2020 , 1-26		1
18	Chagas Disease (American Trypanosomiasis): a Tropical Disease Now Emerging in the United States. 111-134		2
17	Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. <i>Infection and Immunity</i> , 1998 , 66, 5073-81	3.7	70
16	Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for beta-galactosidase. <i>Infection and Immunity</i> , 1999 , 67, 403-9	3.7	56
15	Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. <i>Journal of Clinical Investigation</i> , 1998 , 102, 1062-71	15.9	60

14	Chronic chagasic cardiopathy: the product of a turbulent host-parasite relationship. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 1997 , 39, 53-60	2.2	21
13	Evolutionary behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2000 , 42, 99-109	2.2	59
12	Carvedilol enhances the antioxidant effect of vitamins E and C in chronic Chagas heart disease. <i>Arquivos Brasileiros De Cardiologia</i> , 2013 , 101, 304-10	1.2	15
11	Myocardial Diseases. <i>Medical Radiology</i> , 2000 , 67-94	0.2	
10	Infectious Myocarditis. 2001 , 259-269		
9	Protozoen. 2004 , 1148-1181		
8	Ventricular Arrhythmias and Sudden Cardiac Death in Patients with Chagas Disease. <i>Journal of Cardiology & Current Research</i> , 2017 , 8,	0.1	
7	Nuclear Medicine Methods for Assessment of Chronic Chagas Heart Disease. <i>International Journal of Cardiovascular Sciences</i> , 2020 , 33, 686-696	0.4	
6	Applications of Magnetic Resonance Imaging in Cardiac Disease. 2007 , 142-148		
5	Regional myocardial sympathetic denervation precedes the development of left ventricular systolic dysfunction in chronic Chagas cardiomyopathy.. <i>Journal of Nuclear Cardiology</i> , 2022 , 1	2.1	0
4	Longitudinal Speckle Tracking Strain Abnormalities in Chagas Disease: A Systematic Review and Meta-Analysis.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
3	Revisiting the History of Chagas Disease: "Live to tell". <i>International Journal of Cardiovascular Sciences</i> , 2021 ,	0.4	
2	Diffuse Myocardial Fibrosis and Cardiomyocyte Diameter Are Associated With Heart Failure Symptoms in Chagas Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	
1	Identification and characterization of a novel mouse gene encoding a Ras-associated guanine nucleotide exchange factor: expression in macrophages and myocarditis elicited by <i>Trypanosoma cruzi</i> parasites. 2002 , 72, 1215-1227		5